Sonia Guedan, Principal Investigator, Ramon y Cajal Fellow at August Pi i Sunyer Biomedical Research Institute (IDIBAPS), shared on LinkedIn:
“From the lab to the clinic: ARI-HER2 takes an important step forward!
The ARI-HER2 clinical trial has received regulatory approval by Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), and the site initiation visit has been successfully completed, bringing us one step closer to treating the first patients with HER2-positive metastatic breast cancer.
What makes ARI-HER2 different?
This CAR-T therapy is built around a 4-1BB costimulatory domain and uses a low-affinity receptor to recognize HER2. By using a lower-affinity HER2-binding domain, ARI-HER2 CAR-T cells are designed to preferentially recognize tumor cells expressing high levels of HER2, while minimizing recognition of healthy tissues with lower levels of the protein. This approach aims to improve tumor selectivity and build on the potential of CAR-T therapies for solid tumors.
ARI-HER2 is the result of years of collaborative work with Aleix Prat, Manel Juan, Gonzalo Calvo Rojas, Eulalia Olesti, Julio Delgado and many researchers and clinicians at Hospital Clínic de Barcelona and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). The involvement of SOLTI, Hospital 12 de Octubre and Clínica Universidad de Navarra, together with the support of the Asociación Española contra el Cáncer (AECC), has been essential in bringing this project forward.
And there is more to come?
We hope to share very soon the manuscripts covering the ARI-HER2 story. Looking forward to sharing more about the science behind this project soon!”

You can also read:
